Grants and Contributions:
Title:
Formulation of Desmopressin Acetate Injection to Replace Chlorobutanol in Proof-of-Concept Study
Agreement Number:
1030900
Agreement Value:
$41,000.00
Agreement Date:
Jun 2, 2025 - Jan 30, 2026
Description:
The project aims to develop a novel and improved, multi-dose formulation of desmopressin acetate injection.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Markham, Ontario, CA L3P 2T4
Reference Number:
172-2025-2026-Q1-1030900
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
817994767
Recipient Type:
For-profit organization
Recipient's Operating Name:
KVR Pharmaceuticals
Recipient's Legal Name:
KVR PHARMACEUTICALS INC.
Federal Riding Name:
Markham--Stouffville
Federal Riding Number:
35054
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410